Abstract

We aimed to assess current treatment patterns and outcomes in elderly patients with localized gastric and esophageal (ge) cancers. This retrospective analysis considered patients 75 years of age or older with ge cancers treated during 2012-2014. Patient demographics and tumour characteristics were collected. Overall survival (os) and disease-free survival were assessed by univariable and multivariable Cox proportional hazards regression, adjusting for demographics. Logistic regression analyses were used to examine factors affecting treatment choices. The 110 patients in the study cohort had a median age of 81 years (range: 75-99 years). Primary disease sites were esophageal (55%) and gastric (45%). Treatment received included radiation therapy alone (29%), surgery alone (26%), surgery plus perioperative therapy (14%), chemoradiation alone (10%), and supportive care alone (14%). In multivariable analyses, surgery (hazard ratio: 0.48; 95% confidence interval: 0.26 to 0.90; p = 0.02) was the only independent predictor for improved os. Patients with a good Eastern Cooperative Oncology Group performance status (p = 0.008), gastric disease site (p = 0.02), and adenocarcinoma histology (p = 0.01) were more likely to undergo surgery. At our institution, few patients 75 years of age and older received multimodality therapy for localized ge cancers. Outcomes were better for patients who underwent surgery than for those who did not. To ensure optimal treatment selection, comprehensive geriatric assessment should be considered for patients 75 years of age and older with localized ge cancers.

Highlights

  • In part because of an aging population, the incidence of cancer is expected to increase by 67% in people 65 years of age and older from 2010 to 20301

  • To ensure optimal treatment selection, comprehensive geriatric assessment should be considered for patients 75 years of age and older with localized ge cancers

  • 26% of patients are 75 years of age or older when they are diagnosed with cancer[6], and yet only 10% of that group of patients is enrolled into U.S National Cancer Institute a These authors contributed to the present work

Read more

Summary

Introduction

In part because of an aging population, the incidence of cancer is expected to increase by 67% in people 65 years of age and older from 2010 to 20301. Cancer is typically a disease of the elderly, no cut-off age has been universally accepted for defining “elderly,” 65 years is the accepted age in most high-income countries. Despite the increasing incidence and prevalence of cancer among elderly individuals, that population has been underrepresented in clinical trials[3,4,5]. TREATMENT OF GASTROESOPHAGEAL PATIENTS 75 YEARS OF AGE AND OLDER, Natori et al. We aimed to assess current treatment patterns and outcomes in elderly patients with localized gastric and esophageal (ge) cancers

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.